Biomerieux SA
F:EYWN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biomerieux SA
F:EYWN
|
FR |
|
B
|
Bioventus Inc
NASDAQ:BVS
|
US |
|
DENTSPLY SIRONA Inc
F:DY2
|
US |
|
Sarimelati Kencana Tbk PT
IDX:PZZA
|
ID |
|
Tatton Asset Management PLC
F:2T7
|
UK |
|
P
|
PCF Group SA
WSE:PCF
|
PL |
|
Smith & Nephew PLC
F:NPW1
|
UK |
|
S
|
Sihuan Pharmaceutical Holdings Group Ltd
OTC:SHPHF
|
CN |
Intrinsic Value
Is EYWN undervalued or overvalued?
See the intrinsic value estimate for 
Biomerieux SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
EYWN looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with EYWN’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Biomerieux Does
bioMérieux makes laboratory tests that help doctors and companies find microbes and understand whether a sample is safe. Its products include testing instruments, disposable reagents, software, and service contracts. In hospitals and public labs, these tests are used to identify infections and guide treatment decisions.
- Headquarters
- France FR
- Employees
- 14 894
- IPO date
- Jun 7, 2004
Biomerieux has no economic moat
Hospitals, laboratories and industrial customers can choose among competing diagnostic systems, and bioMérieux’s products do not become more valuable just because more customers use them. Its strong presence in some areas does not prevent rivals from competing for buyers or guarantee that customers will pay more for its name alone.
Read the full moat analysis
Earnings Waterfall
Biomerieux SA
The intrinsic value for Biomerieux SA (EYWN) under the Base Case is hidden EUR.
Compared with the current market price of 88.35 EUR, the stock appears hidden.